DTIL logo

Precision BioSciences, Inc.

DTIL
Healthcare|Biotechnology|US
$10.60
+0.73 (+7.40%)
Tangible Book / Share
$1.85
Cash / Share
$2.98
Next Earnings Report
Mar 11, 2027
EPS est. -$0.99 · Revenue est. $1.3M
Financing Filings (last 12 months)
3
Shelf registrations / offering prospectuses — latest Nov 6, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (42)

Dec 2026
Est. completion
P1HEPATITIS B CHRONIC
Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B
NCT06680232n=45
Dec 2026
Est. completion
P1Non-Hodgkin Lymphoma
PIC1 Injection Therapy for Relapsed/Refractory B-NHL
NCT07456371n=18
Dec 2026
Est. completion
P3Developmental and Epileptic Encephalopathy 1
A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine
NCT07010471n=160
Dec 2026
Est. completion
P3Epileptic Encephalopathy
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety
NCT07019922n=40
Dec 2026
Est. completion
P1Advanced Lung Cancer
A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer
NCT06768151n=48
Dec 2026
Est. completion
P1Colorectal Cancer
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
NCT06043466n=30
Dec 2026
Est. completion
P1P2Multiple Myeloma
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
NCT04271644n=80
Dec 2026
Est. completion
P1P2B-ALL
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL
NCT04781634n=40
Dec 2026
Est. completion
P1P2Multiple Myeloma
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
NCT04776330n=80
Dec 2026
Est. completion
P1Ovarian Cancer
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer
NCT06215950n=36
Jan 2027
Est. completion
P3Focal Epilepsy
Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures
NCT07505004n=300
Jan 2027
Est. completion
NABone Tumor
U.S. Prospective Evaluation of EPIONE Device for Percutaneous MSK Procedures
NCT07325578n=60
Mar 2027
Est. completion
Prostate Cancer
Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer
NCT03957252n=2,800
Mar 2027
Est. completion
P1T-ALL/Lymphoma
Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies
NCT06909474n=15
Apr 2027
Est. completion
Overweight, Infant
Lille Study for Childhood Health Promotion
NCT05121090n=460
Apr 2027
Est. completion
NACytomegalovirus Viremia
CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary Immunodeficiency
NCT07015801n=1
May 2027
Est. completion
P1Peritoneal Metastases From Colorectal Cancer
CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal Metastases
NCT07247396n=12
Jun 2027
Est. completion
P1AML (Acute Myeloid Leukemia)
Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCN
NCT06690827n=30
Jul 2027
Est. completion
P2Mild Cognitive Impairment
Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)
NCT04765137n=20
Jul 2027
Est. completion
P1Juvenile Dermatomyositis
Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis
NCT06569472n=10

Awaiting Results (5)

Trials past primary completion date but still active — data readout may be imminent.

Jun 2026
P1P2
Study of NEO-201 in Solid Tumors Expansion Cohorts
NCT03476681
May 2026
NA
CONtiNuous glucosE Monitoring (CGM) in People wiTh Type 2 Diabetes Not on Insulin
NCT06601166
Apr 2026
P1P2
A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy
NCT05737784
Nov 2025
P2P3
A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)
NCT05818553
Apr 2025
P1
Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus
NCT06222853

Recent Press Releases

Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Nov 5, 2026 · Business Wire
Precision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral Cure
Nov 5, 2026 · Business Wire
Precision BioSciences Announces Positive DSMB Safety Review Supporting Additional PBGENE-DMD Dosing in Phase 1/2 FUNCTION-DMD Study
Nov 5, 2026 · Business Wire
Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 3, 2026 · Business Wire
Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026
Oct 29, 2026 · Business Wire
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026
Oct 8, 2026 · Business Wire
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
Aug 24, 2026 · Business Wire

SEC Filings (82)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 6, 20268-KMaterial eventDocumentIndex
Nov 6, 2026424B5Offering prospectusDocumentIndex
Nov 5, 2026FWPDocumentIndex
Nov 5, 20268-KMaterial eventDocumentIndex
Nov 3, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Nov 3, 20268-KMaterial eventDocumentIndex
Nov 3, 202610-QQuarterly reportDocumentIndex
Oct 27, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 24, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 24, 20268-KMaterial eventDocumentIndex
Aug 7, 2026S-8Employee stock planDocumentIndex
Aug 6, 202610-QQuarterly reportDocumentIndex
Aug 6, 20268-KMaterial eventDocumentIndex
Jul 29, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jul 27, 20268-KMaterial eventDocumentIndex
Jul 20, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jul 1, 20268-KMaterial eventDocumentIndex
Jun 16, 20268-KMaterial eventDocumentIndex
May 27, 20268-KMaterial eventDocumentIndex
May 26, 20268-KMaterial eventDocumentIndex
May 5, 202610-QQuarterly reportDocumentIndex
May 5, 20268-KMaterial eventDocumentIndex
Apr 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Apr 8, 2026ARSAnnual report to holdersDocumentIndex
Apr 8, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 8, 2026DEF 14AProxy / shareholder voteDocumentIndex
Mar 27, 2026PRE 14AProxy / shareholder voteDocumentIndex
Mar 17, 20268-KMaterial eventDocumentIndex
Mar 12, 202610-KAnnual reportDocumentIndex
Mar 12, 20268-KMaterial eventDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 11, 20268-KMaterial eventDocumentIndex
Feb 10, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jan 27, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jan 22, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jan 13, 20268-KMaterial eventDocumentIndex
Jan 7, 2026EFFECTDocumentIndex
Dec 30, 2025S-3Shelf registrationDocumentIndex